Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer - Staging the aging.

Abstract

•Older patients are still underrepresented in randomized controlled clinical trials.•Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit.•Older patients experience more side effects, than their younger counterparts.•Prospective "real-world" data is needed in unselected older women with ovarian cancer receiving PARP-inhibitors.

• Authors: G Liposits, S M Lichtman
• Journal: Gynecologic oncology reports (Gynecol Oncol Rep) Vol. 35 Pg. 100710 (Feb 2021) ISSN: 2352-5789 [Print] Netherlands
• PMID: 33553556 (Publication Type: Journal Article)
• Copyright: © 2021 The Author(s).